Amaya Virós

6.1k total citations · 1 hit paper
46 papers, 3.3k citations indexed

About

Amaya Virós is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Amaya Virós has authored 46 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Molecular Biology and 11 papers in Dermatology. Recurrent topics in Amaya Virós's work include Cutaneous Melanoma Detection and Management (18 papers), Melanoma and MAPK Pathways (16 papers) and Skin Protection and Aging (8 papers). Amaya Virós is often cited by papers focused on Cutaneous Melanoma Detection and Management (18 papers), Melanoma and MAPK Pathways (16 papers) and Skin Protection and Aging (8 papers). Amaya Virós collaborates with scholars based in United Kingdom, Spain and United States. Amaya Virós's co-authors include Richard Marais, María Romina Girotti, James Larkin, Erik Sahai, Berta Sanchez‐Laorden, Steven Hooper, Robert Hayward, Boris C. Bastian, Martin Cook and Malin Pedersen and has published in prestigious journals such as Nature, Nature Medicine and Nature Communications.

In The Last Decade

Amaya Virós

44 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

2015 420 citations María Romina Girotti, Amaya Virós et al. Cancer Cell profile →

Peers

Countries citing papers authored by Amaya Virós

Since Specialization

Citations

This map shows the geographic impact of Amaya Virós's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amaya Virós with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amaya Virós more than expected).

Fields of papers citing papers by Amaya Virós

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amaya Virós. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amaya Virós. The network helps show where Amaya Virós may publish in the future.

Co-authorship network of co-authors of Amaya Virós

This figure shows the co-authorship network connecting the top 25 collaborators of Amaya Virós. A scholar is included among the top collaborators of Amaya Virós based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amaya Virós. Amaya Virós is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer 2024 ·Molecular Cancer ·(unknown), L Wilson, Helen Adderley, Antonio Martínez‐López, Matthew J. Baker, J. Searle, (unknown), Timothy Budden, Mihaela Aldea, (unknown), (unknown), Amaya Virós, B. Besse, Heather A. Wakelee, Fiona Blackhall, Sonia Castillo‐Lluva, Colin R. Lindsay, Angeliki Malliri	10
2	Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross‐sectional study in 684 melanoma patients 2023 ·Pigment Cell & Melanoma Research ·(unknown), (unknown), (unknown), Zaida García‐Casado, (unknown), Celia Requena, V. Través, Amaya Virós, Rajiv Kumar, Eduardo Nagore	0
3	3D Bioprinting: An Enabling Technology to Understand Melanoma 2022 ·Cancers ·(unknown), Cian Vyas, (unknown), Rúben F. Pereira, Amaya Virós, Paulo Bártolo	13
4	Female Immunity Protects from Cutaneous Squamous Cell Carcinoma 2021 ·Clinical Cancer Research ·Timothy Budden, Caroline Gaudy‐Marqueste, Sarah Craig, Yuan Hu, Charles H. Earnshaw, (unknown), (unknown), Victoria Akhras, Patrick Shenjere, Ruth Green, Lynne Jamieson, John T. Lear, (unknown), Carlos Caulı́n, Deemesh Oudit, Simon J. Furney, Amaya Virós	11
5	Ultraviolet light-induced collagen degradation inhibits melanoma invasion 2021 ·Nature Communications ·Timothy Budden, Caroline Gaudy‐Marqueste, Andrew P. Porter, Emily Kay, (unknown), Charles H. Earnshaw, (unknown), Sarah Craig, V. Través, Jean Krutmann, Patricia Müller, (unknown), Sara Zanivan, Angeliki Malliri, Simon J. Furney, Eduardo Nagore, Amaya Virós	53
6	Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development 2021 ·Cancers ·(unknown), María Peña-Chilet, Zaida García‐Casado, (unknown), Celia Requena, José Bañuls, José Antonio López‐Guerrero, (unknown), V. Través, Joaquı́n Dopazo, Amaya Virós, Rajiv Kumar, Eduardo Nagore	7
7	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma 2020 ·ESMO Open ·Rebecca Lee, Garima Khandelwal, Franziska Baenke, Alessio Cannistraci, Kenneth G. MacLeod, Piyushkumar A. Mundra, Garry Ashton, Amit Kumar Mandal, Amaya Virós, Gabriela Gremel, Elena Galvani, Matthew Smith, Neil O. Carragher, Nathalie Dhomen, Crispin Miller, Paul Lorigan, Richard Marais	3
8	Histologic Features Associated With an Invasive Component in Lentigo Maligna Lesions 2019 ·JAMA Dermatology ·(unknown), (unknown), Amaya Virós, Celia Requena, Onofre Sanmartín, V. Través, Eduardo Nagore	14
9	Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface 2017 ·Nature Communications ·Haoran Tang, (unknown), Grazia Saturno, Amaya Virós, Duncan L. Smith, Gianpiero Di Leva, (unknown), Dan Niculescu‐Duvaz, Filipa M. Lopes, Louise D. Johnson, Nathalie Dhomen, Caroline J. Springer, Richard Marais	73
10	Mechanisms of Drug Resistance in Melanoma 2017 ·Handbook of experimental pharmacology ·(unknown), Amaya Virós	78
11	Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells 2015 ·Molecular Oncology ·Franziska Baenke, Barbara Chaneton, Matthew Smith, Niels van den Broek, Kate Hogan, Haoran Tang, Amaya Virós, Matthew J. Martin, Laura C.A. Galbraith, María Romina Girotti, Nathalie Dhomen, Eyal Gottlieb, Richard Marais	131
12	A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity 2015 ·Nature Communications ·(unknown), Gwendoline Gros, Christine Longvert, Malin Pedersen, Valérie Petit, Zackie Aktary, Amaya Virós, Franck Gesbert, Véronique Delmas, Florian Rambow, Boris C. Bastian, Andrew D. Campbell, Sophie Colombo, Isabel Puig, Alfonso Bellacosa, Owen J. Sansom, Richard Marais, Léon C.L.T. van Kempen, Lionel Larue	55
13	Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes 2013 ·Cancer Discovery ·Malin Pedersen, Heidi V.N. Küsters‐Vandevelde, Amaya Virós, Patricia J.T.A. Groenen, Berta Sanchez‐Laorden, (unknown), (unknown), W.O. Renier, Jolanda Schieving, Ion Niculescu‐Duvaz, Caroline J. Springer, Benno Küsters, Pieter Wesseling, Willeke A.M. Blokx, Richard Marais	51
14	Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. 2013 ·Cancer Research ·María Romina Girotti, Malin Pedersen, Berta Sanchez‐Laorden, Amaya Virós, Samra Turajlic, Dan Niculescu‐Duvaz, Alfonso Zambon, John Sinclair, Andrew Hayes, Martin Gore, Caroline J. Springer, James Larkin, Claus Jørgensen, Richard Marais	1
15	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma 2012 ·Cancer Discovery ·María Romina Girotti, Malin Pedersen, Berta Sanchez‐Laorden, Amaya Virós, Samra Turajlic, Dan Niculescu‐Duvaz, Alfonso Zambon, John Sinclair, Andrew Hayes, Martin Gore, Paul Lorigan, Caroline J. Springer, James Larkin, Claus Jørgensen, Richard Marais	272
16	Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A 2012 ·Cancer Discovery ·Matthew J. Martin, Robert Hayward, Amaya Virós, Richard Marais	116
17	Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A 2011 ·Cancer Cell ·Imanol Arozarena, Berta Sanchez‐Laorden, Leisl Packer, Cristina Hidalgo-Carcedo, Robert Hayward, Amaya Virós, Erik Sahai, Richard Marais	168
18	Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure 2010 ·Pigment Cell & Melanoma Research ·(unknown), Renato Salemi, William K. Murray, Angela Tan, Wendy Liu, Amaya Virós, Alexander Dobrovic, John W. Kelly, Grant A. McArthur	87
19	Eruptive Juvenile Xanthogranuloma Associated with Relapsing Acute Lymphoblastic Leukemia 2008 ·Pediatric Dermatology ·Gloria Aparicio, Jordi Mollet, R. Bartralot, D. Bodet, Cristina de las Heras, (unknown), Amaya Virós, Vicente García‐Patos	11
20	Improving Melanoma Classification by Integrating Genetic and Morphologic Features 2008 ·PLoS Medicine ·Amaya Virós, Jane Fridlyand, Jürgen Bauer, (unknown), Claus Garbe, Daniel Pinkel, Boris C. Bastian	275

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact